A Phase 4 interventional study of carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) and sodium hyaluronate 0.18% (VISMED® Multi) in Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Allergan. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-21.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.
This study's enrollment of 82 is close to the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.
Browse Keratoconjunctivitis Sicca studies →Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Compared within Keratoconjunctivitis Sicca, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dry Eye Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
sodium hyaluronate 0.18% (VISMED® Multi)
Drug: sodium hyaluronate 0.18% (VISMED® Multi)
One drop in each eye three to six times daily, as needed
Also known as: OPTIVE® MD
One drop in each eye three to six times daily, as needed
Also known as: VISMED® Multi
Change From Baseline in Global Ocular Staining Score at Day 35
Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).
Time frame: Baseline, Day 35
Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35
Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.
Time frame: Baseline, Day 35
| Milestone | Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | Sodium Hyaluronate 0.18% (VISMED® Multi) |
|---|---|---|
| Started | 41 | 41 |
| Completed | 36 | 34 |
| Not completed | 5 | 7 |
Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).
| Number on a scale (score) | Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | Sodium Hyaluronate 0.18% (VISMED® Multi) |
|---|---|---|
| Baseline | 5.4 ± 1.59 | 5.9 ± 1.47 |
| Day 35 | -1.8 ± 1.95 | -1.8 ± 2.30 |
Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.
| Number on a scale (score) | Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | Sodium Hyaluronate 0.18% (VISMED® Multi) |
|---|---|---|
| Baseline | 49.05 ± 17.060 | 51.98 ± 18.164 |
| Day 35 | -13.58 ± 19.047 | -13.66 ± 16.542 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | — | 1/41 (2.4%) | 0/41 (0%) |
| Sodium Hyaluronate 0.18% (VISMED® Multi) | — | 1/38 (2.6%) | 0/38 (0%) |
| Event | Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | Sodium Hyaluronate 0.18% (VISMED® Multi) |
|---|---|---|
| Amyotrophic Lateral SclerosisNervous system disorders | 0/41 | 1/38 |
| Upper Limb FractureInjury, poisoning and procedural complications | 1/41 | 0/38 |
| Age, Customized(participants) | Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | Sodium Hyaluronate 0.18% (VISMED® Multi) | Total |
|---|---|---|---|
| <65 years | 22 | 29 | 51 |
| >=65 years | 19 | 12 | 31 |
| Sex: Female, Male(Participants) | Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD) | Sodium Hyaluronate 0.18% (VISMED® Multi) | Total |
|---|---|---|---|
| Female | 36 | 38 | 74 |
| Male | 5 | 3 | 8 |
The record gives a start of Nov 2009, a primary completion of Jul 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carboxymethylcellulose